Therapeutic Restoration of Immune Function through iPSC-derived Human Thymic Epithelial Cells Post author: Post published:June 29, 2026 Post category: Continue ReadingTherapeutic Restoration of Immune Function through iPSC-derived Human Thymic Epithelial Cells
Hypoimmune Stem Cell–Derived Islets: A Next-Generation Cell Therapy Toward a Functional Cure for Type 1 Diabetes Post author: Post published:June 29, 2026 Post category: Continue ReadingHypoimmune Stem Cell–Derived Islets: A Next-Generation Cell Therapy Toward a Functional Cure for Type 1 Diabetes
Regenerating the Acutely Infarcted Heart with iPSC-Ventricular Cardiomyocytes. Post author: Post published:June 29, 2026 Post category: Continue ReadingRegenerating the Acutely Infarcted Heart with iPSC-Ventricular Cardiomyocytes.
Stem Cell-Engineered Off-The-Shelf CAR-NKT Cell Therapy for Multiple Sclerosis Post author: Post published:June 29, 2026 Post category: Continue ReadingStem Cell-Engineered Off-The-Shelf CAR-NKT Cell Therapy for Multiple Sclerosis
A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent Cardiovascular Events Post author: Post published:June 29, 2026 Post category: Continue ReadingA First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent Cardiovascular Events
Gene Therapy for Alpha-1 Anti-Trypsin Deficiency Post author: Post published:June 29, 2026 Post category: Continue ReadingGene Therapy for Alpha-1 Anti-Trypsin Deficiency
Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies Post author: Post published:June 29, 2026 Post category: Continue ReadingLate-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies
Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9 Post author: Post published:June 29, 2026 Post category: Continue ReadingAdvancement of a myotropic, liver-detargeting therapy for LGMD2i/R9
A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia Post author: Post published:June 29, 2026 Post category: Continue ReadingA first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia
Microglia replacement therapy for CSF1R-related Leukoencephalopathy Post author: Post published:June 29, 2026 Post category: Continue ReadingMicroglia replacement therapy for CSF1R-related Leukoencephalopathy
